|
|
 |
 |
| |
 Printable version |
Prostate Cancer Screening: the medico-legal risk of “real life” |
Médecine. Volume 8, Number 3, 118-22, Mars 2012, Référentiels
|
 Résumé
Article gratuit
|
Author(s) : Jean-Pierre Vallée, Éric Drahi, Pierre Gallois, Yves Le Noc |
Summary : Since 1998, The ANAES and then the HAS have consistently stressed that the PSA is not indicated in the detection of prostate cancer or in the diagnosis of a disease other than prostate cancer. PSA-based screening results in small or no reduction in prostate cancer-specific mortality and it is associated with subsequent harms related to treatments, some of which may be unnecessary.
The prostate cancer is not more common when there are moderate urinary disorders and does not develop in a man over 50 years. The PSA in patients with symptoms and when they are non-applicant is therefore an opportunity.
It is unlikely that a highly evolving cancer when it is at diagnosis could have been preceded by a less aggressive form with better prognosis in case of early intervention. There is no need to offer screening to a man who does not asks just because he is over 50. There is also no reason to refuse this screening to anyone who requests it, but this requires full information on what would follow a positive screening.
|
Keywords : Prostate-Specific Antigen\; Early Detection of Cancer\; Prostatic Neoplasms |
|
